Articles from Lirum Therapeutics, Inc.

New York, NY, April 29, 2025 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that new positive data on LX-101 against an increasingly wide variety of cancer types was selected for presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago. LX-101 is a novel clinical-stage payload-bearing targeted therapy directed to the insulin-like growth factor 1 receptor (IGF-1R) being developed in oncology and autoimmune indications.

New York, NY, March 19, 2025 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that the Company has been invited to present at the renowned Gordon Research Conference Meeting on March 19th in Ventura, California.

New York, NY, March 17, 2025 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that its first data on LX-101 in Thyroid Eye Disease (TED) have been selected for presentation at the 51st Annual Meeting of the North American Neuro-Ophthalmology Society (NANOS), March 15-20 in Tucson, Arizona.

New York, NY, March 04, 2025 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today the presentation of additional positive data on LX-101 at the 2025 ESMO Targeted Anticancer Therapies Congress (TAT) in Paris, France. LX-101, a novel clinical-stage payload-bearing targeted therapy directed to the insulin-like growth factor 1 receptor (IGF-1R), was selected for two presentations at this year’s TAT conference.

New York, NY, April 04, 2024 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (Lirum), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today the upcoming presentation of positive data on LX-101, a novel clinical-stage targeted therapy directed to the insulin-like growth factor 1 receptor (IGF-1R), at the 2024 American Association for Cancer Research (AACR) Annual Meeting being held from April 5-10 in San Diego, California.

New York, NY, March 14, 2024 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today the acceptance for presentation of positive data on LX-101, a novel clinical-stage targeted therapy directed to the insulin-like growth factor 1 receptor (“IGF-1R”), at the 2024 European Society for Medical Oncology (“ESMO”) Sarcoma and Rare Cancers Congress being held from March 14-16 in Lugano, Switzerland.

New York, NY, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that it will present positive data on LX-101, a novel clinical-stage targeted therapy directed to the insulin growth factor-1 receptor (IGF-1R), in patients with high IGF-1R tumor expression at the 2024 European Society for Medical Oncology (ESMO) Targeted Anticancer Therapies Congress in Paris, France on Monday, February 26th at 5:15 PM CET (11:15 ET).

New York, NY, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that management is participating in the 13th Annual LifeSci Partners Corporate Access Event, which is taking place January 8-10, 2024 at the Beacon Grand Hotel in San Francisco, California during J.P. Morgan week. The presentation from this event can be accessed on Lirum’s website, under the Investors and Media section.

New York, NY, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, today announced the presentation of positive data at the 2023 Connective Tissue Oncology Society meeting in Dublin, Ireland.

New York, NY, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that Peter McDonald, the CEO of Lirum, will present at the 2023 ThinkEquity Conference on Thursday, October 19, 2023, at 2:00 PM ET. The conference will be held at the Mandarin Oriental Hotel in New York, NY.

NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, today announced the presentation of positive data at the 7th Cancer World Congress in Palermo, Italy. 

New York, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (the “Company” or “Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, today announced that it has closed a private placement, which resulted in gross proceeds to Lirum of over $7 million, before deducting offering expenses. Net proceeds will be used by Lirum primarily to advance its clinical and preclinical studies, for working capital, and to potentially expand its product candidate pipeline.